Has Peter Kowey, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,554,989 in general payments to Peter Kowey, MD across 472 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Kowey, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Kowey, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Kowey, MD

Cardiovascular Disease · Wynnewood, PANPI 1114922945

Payments from drug & device makers

$1,554,989in general payments, 2019–2025

Across 472 payments — averaging $3294.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$231K
UCB SA$174K
GSK$156K
AbbVie$124K
E.r. Squibb & Sons, L.L.C.$93K
Sanofi-aventis U.S. LLC$81K
plus $696K from 46 others

$177,715in research payments, 2019–2025

Across 99 payments — averaging $1795.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$66K
E.r. Squibb & Sons, L.L.C.$41K
Astrazeneca UK Limited$16K
Sanofi-aventis U.S. LLC$14K
AbbVie$11K
Amryt Pharma Holdings Ltd$9K
plus $21K from 6 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	69	$230,655
UCB SA	37	$174,300
GSK	43	$155,753
AbbVie(2 entities)	54	$123,850
E.r. Squibb & Sons, L.L.C.	10	$93,313
Sanofi-aventis U.S. LLC	31	$81,209
Braemar Manufacturing, LLC	1	$66,000
Redhill Biopharma Inc.	5	$56,443
Sanofi US Services Inc.	7	$54,378
Astrazeneca UK Limited	39	$52,969
Novartis Pharma AG	12	$44,437
AstraZeneca	13	$40,186
Novo Nordisk	8	$31,927
Boehringer Ingelheim Pharma GmbH & Co.kg	10	$26,850
UCB Biosciences Inc.	6	$26,400
Modernatx, Inc.	26	$25,840
Amarin Pharma, Inc.	16	$23,677
Daiichi Sankyo Inc.	17	$23,378
Takeda Pharmaceuticals U.S.A., Inc.	11	$20,419
Alnylam Pharmaceuticals Inc.	4	$18,085
Bausch Health US, LLC	4	$17,150
Syndax Pharmaceuticals, Inc.	3	$14,625
Eisai Inc.	1	$12,300
Edwards Lifesciences	3	$12,000
Strongbridge US Inc.	2	$10,200
Bridgebio Pharma, Inc.	3	$9,750
Ardelyx, Inc.	1	$8,450
Akebia Therapeutics Inc	1	$8,400
Mallinckrodt Hospital Products Inc.	1	$8,100
BD	1	$7,200
Ipsen Bioscience Inc.	1	$7,200
Incyte Corporation	3	$6,958
Endologix LLC	1	$6,600
Eli Lilly	1	$6,600
Medtronic(2 entities)	3	$6,000
Philips North America LLC	1	$5,500
Neovasc Medical Inc	1	$5,100
Viiv Healthcare Company	3	$4,117
Novartis	2	$3,789
Boehringer Ingelheim Italia S.p.a.	1	$3,600
Pfizer	2	$3,500
Novo Nordisk AS	1	$3,140
Astellas Pharma Global Development	2	$2,975
Mirum Pharmaceuticals, Inc.	1	$2,925
Travere Therapeutics, Inc.	1	$2,400
Boehringer Ingelheim International GmbH	1	$1,800
Roche Diagnostics Corporation	2	$1,644
Merck	1	$1,635
Mylan Inc.	1	$600
Eagle Pharmaceuticals, Inc.	1	$600
Boston Scientific	2	$37
Getinge USA Sales, LLC	1	$26

How this compares

$1,554,989 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$41,239

Medicare patients

2,970

Services billed

5,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Wynnewood

Danielle DuffyPhiladelphia$29.5M
Venkatesh NadarCamp Hill$18.3M
Hemal GadaWormleysburg$6.7M
Brian DrachmanPhiladelphia$3.8M
William BachinskyMechanicsburg$2.3M
Bonnie KyPhiladelphia$1.9M
Benjamin KalsmithPgh$1.7M
Marielle Scherrer CrosbiePhiladelphia$1.6M
Paul GrenaYardley$1.6M
Chinmay PatelLancaster$1.4M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →